Analyzing RenaissanceRe (RNR) Stock Performance

RenaissanceRe stock is trading -20.39% below its average target price of $269.0 after dropping -3.2% during today's afternoon session. Analysts are giving the Large-Cap Property & Casualty Insurance company an average rating of buy and target prices ranging from $218.0 to $334.0 per share.

RenaissanceRe's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.1%. The stock's short ratio is 3.85. The company's insiders own 1.88% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 98.8%. In conclusion, we believe there is positive market sentiment regarding RenaissanceRe.

Institutions Invested in RenaissanceRe

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 10% 5,497,818 $1,177,302,743
2024-03-31 Blackrock Inc. 9% 4,942,771 $1,058,444,978
2024-03-31 Bank Of New York Mellon Corporation 5% 2,752,016 $589,316,704
2024-03-31 Capital World Investors 5% 2,473,322 $529,637,171
2024-03-31 State Farm Mutual Automobile Insurance Co 5% 2,399,303 $513,786,742
2024-03-31 Orbis Allan Gray Ltd 4% 2,375,616 $508,714,408
2024-03-31 State Street Corporation 4% 2,329,575 $498,855,189
2024-03-31 Egerton Capital (UK) LLP 4% 1,858,824 $398,048,570
2024-03-31 Price (T.Rowe) Associates Inc 3% 1,751,933 $375,158,931
2023-12-31 Boston Partners 3% 1,431,954 $306,638,628
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.